ReviewJournal of innate immunity2012
Streptococcal IdeS and its impact on immune response and inflammation.
Review in Journal of innate immunity, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02426684 (A Phase I/II Trial to Evaluate the Safety and Tolerability of Ides®), which is not on this map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase I/II Trial to Evaluate the Safety and Tolerability of Ides® (IgG Endopeptidase) to Eliminate Donor Specific HLA Antibodies (DSAs) and Prevent Antibody-Mediated Rejection Post-Transplant in Highly-HLA Sensitized Patients.
Who cites it
18 citing papers in PubMed, 42 citations in OpenAlex.
- Trial
- Identification and Characterization of Novel Human IgG-Degrading Enzymes.Biochemistry · 2026Article
- Group A Streptococcal Virulence Factors and Vaccine Development-An Update.Microorganisms · 2026Review
- Therapeutic IgG- and IgM-specific proteases disarm the acetylcholine receptor autoantibodies that drive myasthenia gravis pathology.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- The gut-brain axis: potential reshaping the future of anti-NMDAR encephalitis treatment.Frontiers in immunology · 2025Review
- Article
- Optimising the IgG-degrading enzyme treatment regimen for enhanced adeno-associated virus transduction in the presence of neutralising antibodies.Clinical & translational immunology · 2022Article
- Multicomponent Vaccines against Group A Streptococcus Can Effectively Target Broad Disease Presentations.Vaccines · 2021Article
- Antibody-Dependent Enhancement of Bacterial Disease: Prevalence, Mechanisms, and Treatment.Infection and immunity · 2021Review
- Lack of Opsonic Antibody Responses to Invasive Infections WithFrontiers in microbiology · 2021Article
- Catch Me if You Can: Streptococcus pyogenes Complement Evasion Strategies.Journal of innate immunity · 2019Review
- Human IgG Increases Virulence ofJournal of immunology (Baltimore, Md. : 1950) · 2018Article
- Streptococcal IdeS: therapeutic potential for Guillain-Barré syndrome.Scientific reports · 2015Article
- Article
- A farewell to arms: streptococcal strategies to cope with innate immunity.Journal of innate immunity · 2014Article
- Engineered protease-resistant antibodies with selectable cell-killing functions.The Journal of biological chemistry · 2013Article
- Article
- Posttranslational modifications in innate immunity.Journal of innate immunity · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Survival of the important bacterial pathogen Streptococcus pyogenes relies on its ability to circumvent the antimicrobial actions of innate and specific immune responses and to modulate the inflammatory responses induced during the course of an infection. Inflammatory processes play key roles during streptococcal pathogenesis and streptococcal infections are accompanied by an intense inflammatory state. As an exclusively human pathogen, S. pyogenes has adapted to the various countermeasures employed by its host to fight bacterial infections, in particular to interfere with the effector functions of immunoglobulin G (IgG). For this purpose, S. pyogenes has evolved an IgG-specific endopeptidase, IdeS, which is highly specific for the lower hinge region of IgG. This review summarizes the current knowledge about this intriguing enzyme as well as its role in inflammation and in the attenuation of human immune responses towards streptococcal infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.